Total Funding
92
86
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
33 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
162
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
- Janice Kapty: SVP of Corporate Strategy and Project LeadershipPast Role: MorphoSys, Vice President- Global Program Head Pelabresib
- Douglas Barry: Chief Legal OfficerPast Role: Tango Therapeutics, General Counsel
About the Company
Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused on
three core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy.
Women Led
